PD1/NFAT-Luc/Jurkat
CBP74018
| I. Background | |
|       腫瘤細胞可以借助免疫檢查點(diǎn)受體逃避機體免疫系統的識別和殺傷,因此阻斷免疫檢 查點(diǎn)受體可能是一種廣泛有效的腫瘤免疫治療方法。目前,抗 PD-1/PD-L1 抗體雖然比較 成熟,與抗 CTLA4 抗體類(lèi)似,但由于存在耐藥性,患者的總體有效率較低,因此尋找新 的腫瘤免疫治療靶點(diǎn)迫在眉睫。 Programmed Cell Death Protein 1 (PD-1),一種在激活的 T 細胞上表達的受體,與其配 體 PD-L1 和 PD-L2 結合,負向調節免疫反應。 PD-1 配體存在于大多數癌癥中,PD-1:PD- L1/2 相互作用會(huì )抑制 T 細胞活性,并使癌細胞逃避免疫監視。 PD1/PDL1 信號轉導通路是 腫瘤免疫抑制的重要組成部分,可以抑制 T 淋巴細胞的興奮,增強腫瘤細胞的免疫耐受, 從而實(shí)現腫瘤免疫逃逸。PD1 與 PDL1 結合可以減弱 T 細胞介導的免疫監視,導致免疫反 應缺失,甚至導致 T 細胞凋亡。PD1/PDL1 抑制劑可解除抗腫瘤 T 細胞的免疫抑制,從而 導致 T 細胞增殖并滲透到腫瘤微環(huán)境中并誘導抗腫瘤反應。PD-1:PD-L1/2 通路還參與調節 自身免疫反應,使這些蛋白質(zhì)成為多種癌癥以及多發(fā)性硬化癥、關(guān)節炎、狼瘡和 I 型糖尿 病的有希望的治療靶點(diǎn)。酪氨酸磷酸酶 SHP2 是 T 細胞功能的關(guān)鍵調節因子,它介導 TCR 下游的激活信號以及 PD-1 下游的抑制信號。  | 
		|
| II. Description | |
      PD1 NFAT-Luc Jurkat 報告基因藥靶模型很好的模擬了體內 PD1&PDL1/PDL2 的信號轉 導過(guò)程,原理見(jiàn)下圖所示。![]() ![]() Figure 1. PD1 NFAT-Luc Jurkat 細胞模型原理圖  | 
		|
| III. Introduction | |
| Host Cell: | Jurkat | 
| Expressed gene: | PD1、NFAT-Luciferase | 
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) | 
| Synonym(s): | Programmed cell death 1, PDCD1, PD-1, PD1, SLEB2, CD279, HPD-L, PD1/NFAT, PD-1 NFAT, PD-1/NFAT | 
| Freeze Medium: | 90% FBS+10% DMSO | 
| Culture Medium: | RPMI-1640+10%FBS+800μg/ml hygromycin+1μg/ml puromycin | 
| Mycoplasma Testing: | Negative | 
| Storage: | Liquid nitrogen | 
| Application(s): | Functional(Report Gene) Assay | 
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human | 
| Tissue: | Peripheral blood | 
| Disease: | Acute T cell leukemia | 
| Morphology: | Lymphoblast | 
| Growth Properties: | Suspension | 
| Ⅴ. Representative Data | |
| 
				 
  | 
		|
| 
				 Figure 2. Recombinant PD1/NFAT-Luc/Jurkat stably expressing PD1.  | 
		|
| 
				 
 Figure 3. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001(we strongly suggest to purchase from Cobioer).Dose response of Anti-PD-1 Neutralizing Antibody in PD1 NFAT-Luc Jurkat(C16) with PDL1 TCR Activator CHO (C5).  | 
		|
| 
				    | 
		|
| 
				 Figure 4. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001(we strongly suggest to purchase from Cobioer). Dose response of Anti-PDL1 Neutralizing Antibody in PD1 NFAT-Luc Jurkat(C16) with PDL1 TCR Activator CHO (C5).  | 
		|
| 
				 
 Figure 5. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001(we strongly suggest to purchase from Cobioer). Dose response of Anti-PD1 Neutralizing Antibody in PD1 NFAT-Luc Jurkat(C16) with PDL2 TCR Activator CHO(C1).  | 
		|
![]() Figure 6. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001(we strongly suggest to purchase from Cobioer). Dose response of PD1 Agonist Antibody in PD1 NFAT-Luc Jurkat(C16) with FcγR aAPC Cell(C1).  | 
		|
            


 

